|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
[PtCl<sub>4</sub>(en)] managed to increase presence of CD45+ leukocytes, including F4/80+ macrophages, CD11c+ dendritic cells, CD4+ helper and CD8+ cytotoxic T cells (CTLs) in the lungs, cytotoxic NK, NKT and CTLs in the spleens of tumor bearing mice, resulting with reduction of metastatic lesions in the lungs, indicating its potential to stimulate anti-tumor immune response in vivo.
|
28421385 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the palladium-based barcoding affected the stability of several antigens, the staining with two differently labeled CD45 antibodies was suitable for cells isolated from a patient's blood and tumor.
|
30886872 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While Mo-MuLV only induced Thy-1+ thymomas, v-abl- and BCR-ABL-induced thymomas often contained mixed populations of B220+ and Thy-1+ lymphocytes in the same tumor.
|
8396667 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When lymphocytes were preloaded with immunoliposomes in vitro prior to adoptive therapy, vesicles targeted to both CD45 and CD90 promoted enhanced T-cell expression of granzymes relative to free systemic drug administration, but only targeting to CD45 enhanced accumulation of granzyme-expressing T-cells in tumors, which correlated with the greatest enhancement of T-cell antitumor activity.By contrast, when administered i.v. to target T-cells in vivo, only targeting of a CD90 isoform expressed exclusively by the donor T-cells led to greater tumor regression over equivalent doses of free systemic drug.
|
28231431 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a significant association between specific CD45(neg) subpopulations and tumor subtypes (e.g.
|
26961140 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the combination elicited a robust systemic and tumor-specific immune response with (a) increased percentages of systemic and tumor infiltrated CD45+CD11b+ cells, (b) increased levels of myeloperoxidase (MPO), (c) increased antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP), (d) decreased percentage of immune regulatory cells (CD8+CD69+ cells), and (e) reduced circulating levels of immunosuppressive tMUC1.
|
31114758 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163.
|
31549213 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study examined the influence of CD45-positive cells in liver parenchyma and primary tumors on cumulative survival.
|
30842149 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review shows that the biology of CD45 illuminates that of MM and, more specifically, provides a better delineation of a tumor cell 'hierarchy' of clinical interest.
|
12846811 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the first study which separately analyzes peritumoral stroma and tumor core area in laryngeal squamous cell carcinoma in terms of CD45, CD11b, CD3, MMP-9 and COX-2 expression.
|
29492204 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These spatial light-patterns can be automatically configured to profile (1) "tumor-only" cells plus "tumor-microenvironment-only" cells; (2) unique cell types and rare cell features (e.g., macrophages, CD8, CD3, CD45, PD-L1 on macrophages, PD-L1 on tumors, etc.); (3) spatial gradients around cell-features or tumor features (e.g., excluded boundaries); (4) hypothesis-free spatial grids; (5) simple hand-selected geometric areas (e.g., free-hand software-based "drawing" on tissue regions); and (6) or any combination of the above modalities.
|
31502169 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The prognostic value of programmed cell death ligand 1 (PD-L1) expression in tumor cells and tumor infiltrating lymphocytes (TILs) and the percentage of CD3-, CD20-, CD45- and CD68-positive cells, were also investigated.
|
30735815 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effectiveness of magnetic‑activated cell sorting (MACS) for tumor‑cell enrichment, through the depletion of CD45+ leukocytes in PBMC samples, was also assessed.
|
28849093 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The anti-tumor activity could be attributed to the stimulation of immune cells with an elevated expression of the activation marker CD69 on NK, T and NKT cells and the infiltration of CD45+ immune cells into the solid tumor.
|
24242212 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data identify a tumor suppressor role for CD45 in T-cell acute lymphoblastic leukemia.
|
22438252 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Statistical performance of image cytometry for DNA, lipids, cytokeratin, & CD45 in a model system for circulation tumor cell detection.
|
28608985 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, antibodies against CD45, cytokeratin, EpCAM, and cleaved-PARP (cPARP) were used to differentiate nonapoptotic epithelial cells from leukocytes, while measurements of DNA content to determine aneuploidy (DAPI stain) allowed for distinction between tumor and normal epithelial cells.
|
23300058 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sole inhibition of VEGFR-1 signaling led to a strong reduction of the CD45-positive inflammatory infiltrate in the tumor tissue.
|
17230507 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Since the immune status of the tumor microenvironment could play a role in the history of disease, we evaluated the expression of CD45, CD14, ARG1, CD163, CD4, FOXP3, Perforin-1 (PRF1), Granzyme B (GRMB), and IL-10 mRNAs in primary tumors at diagnosis from children with metastatic NB and tested whether the transcript levels are significantly associated to event-free and overall survival (EFS and OS, resp.).
|
26161395 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients who had their tumor sequenced by either FoundationOne (<i>n</i> = 13) or the institutional T200/T200.1 panels (<i>n</i> = 7) were included in this study.
|
29731991 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neither analysis of the T-cell receptor repertoire nor CD45 isoform expression of T(reg) cells from patients with CLL provided evidence for chronic (tumor) antigenic stimulation as a possible cause for T(reg) cells expansion in CLL.
|
19452318 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mouse lymphoma xenograft experiments showed minimal toxicity, excellent tumor-specific targeting of the fusion protein and radiolabeled DOTA-biotin in vivo, marked inhibition of tumor growth, and cured 100% of mice bearing CD45-expressing tumors.
|
16585217 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MMP9, CD44, DLL4, FOXP1, MERTK, and PTPRC genes were found more expressed in tumors re-growing after cisplatinum treatment than in untreated tumors.
|
26910918 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LIMD2 and PTPRC (CD45) showed a statistically significant difference in expression between tumor and metastatic samples (P < 0.0045), and an additional gene (LTB) had borderline significance.
|
17699795 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lectin presence in the tumor and endothelial cells was positively correlated, while a negative relationship to the number of CD45-positive lymphocytes was demonstrated.
|
19331133 |
2009 |